Streptococcus pneumoniae
Morphology | Aerotolerant, gram positive diplococci, lancet-shaped, occur in pairs, or short, tight chains. |
---|---|
Disease | Pneumonia, otitis media, meningitis. |
Zoonosis |
Possible, by bite wound or exposure to infected animals. |
Host Range | Humans and Animals. |
---|---|
Modes of Transmission | Direct contact with aerosol droplets. Direct oral and mucous membrane contact. Indirectly through articles freshly soiled with respiratory discharges. |
Signs and Symptoms | Shaking chills, chest pain, dyspnea, fever, productive cough, and sinusitis. Can cause middle ear infections. Can progress to pneumonia, bacteremia, meningitis. |
Infectious Dose | Unknown |
Incubation Period | Generally 1-3 days |
Prophylaxis | Pneumococcal conjugate vaccine (PCV7) and pneumococcal polysaccharide vaccine (PPV23) |
---|---|
Vaccines | Pneumococcal conjugate vaccine (PCV13) and pneumococcal polysaccharide vaccine (PPV23). Vaccination is recommended for all children under 5 years of age, all adults over 65 years of age, and high risk individuals of any age, including individuals with underlying medical conditions such as HIV or sickle-cell disease. |
Treatment | Variable susceptibility to: penicillin, tetracycline, cefotaxime, levofloxacin, erythromycin, and flouroquinolines, moxifloxacin and gatifloxacin, telithromycin, vancomycin, linezolid. |
Surveillance | Monitor for symptoms of infection |
MSU Requirements | Report any exposures |
Laboratory Acquired Infections (LAIs) | 78 documented cases since 1999 |
---|---|
Sources | Sputum, blood, respiratory secretions, throat swabs, parenteral inoculation. Cultures, frozen stocks, other samples described in IBC protocol. |
Canadian MSDS: | http://www.phac-aspc.gc.ca/lab-bio/res/psds-ftss/index-eng.php |
---|---|
BMBL
|
https://www.cdc.gov/labs/BMBL.html |
CDC | https://www.cdc.gov/pneumococcal/clinicians/streptococcus-pneumoniae.html |
NIH Guidelines | https://osp.od.nih.gov/wp-content/uploads/NIH_Guidelines.pdf |
Risk Group 2
|
Agents that are associated with human disease which is rarely serious and for which preventive or therapeutic interventions are often available. |
---|---|
BSL2
|
For all procedures involving suspected or known infectious specimen or cultures.
|
ABSL2
|
For all procedures utilizing infected animals.
|
Small
|
Notify others working in the lab. Remove PPE and don new PPE. Cover area of the spill
with absorbent material and add fresh 1:10 bleach:water. Allow 20 munutes (or as directed)
of contact time. After 20 minutes, cleanup and dispose of materials.
|
---|---|
Large
|
|
Mucous membrane
|
Flush eyes, mouth, or nose for 5 minutes at eyewash station.
|
---|---|
Other Exposures
|
Wash area with soap and water for 5 minutes.
|
Reporting |
Immediately report incident to supervisor, complete a First Report of Injury form, and submit to Safety and Risk Management.
|
Medical Follow-up
|
During business hours: Bridger Occupational Health 3406 Laramie Drive. Weekdays 8am -6pm. Weekends 9am-5pm
After business hours: Bozeman Deaconess Hospital Emergency Room 915 Highland Blvd Bozeman, MT |
Disinfection | Susceptible to 1:10 bleach:water, 70 % ethanol and 2 % gluteraldehyde |
---|---|
Inactivation | Inactivated by moist heat (15 minutes at 121° C) and dry heat (1 hour at 160-170° C). |
Survival Outside Host | Mouse carcasses – 180 to 270 days, sputum at room temperature survives 7 days, and gauze survives 2 to 15 days. |
Minimum PPE Requirements
|
Lab coat, disposable gloves, safety glasses, closed toed shoes, long pants
|
---|---|
Additional Precautions
|
Additioanl PPE may be required depending on lab specific SOPs and IBC Protocol. |